KENNETH FRAZIER RESIGNS AS CEO OF PHARMA COMPANY MERCK & CO

Highlights

• Chief Executive Officer (CEO) Kenneth Frazier has decided to step down from his post at the end of June and will be replaced by the Chief Financial Officer Robert Davis

• The drugmaker said Frazier, 66, will continue to serve on its board as executive chairman for a transition period which will be determined by the board

• As per the IBES data from Refinitiv, Merck also forecast 2021 ad....